Literature DB >> 21846421

Genetic variation in 5-hydroxytryptamine transporter expression causes adaptive changes in 5-HT₄ receptor levels.

Katie Ann Jennings1, Cecilie Löe Licht, Aynsley Bruce, Klaus-Peter Lesch, Gitte Moos Knudsen, Trevor Sharp.   

Abstract

Genetic variation in 5-HT transporter (5-HTT) expression is a key risk factor for psychiatric disorder and has been linked to changes in the expression of certain 5-HT receptor subtypes. This study investigated the effect of variation in 5-HTT expression on 5-HT₄ receptor levels in both 5-HTT knockout (KO) and overexpressing (OE) mice using autoradiography with the selective 5-HT₄ receptor radioligand, [³H]SB207145. Compared to wild-type (5-HTT⁺/⁺) controls, homozygous 5-HTT KO mice (5-HTT⁻/⁻) had reduced 5-HT₄ receptor binding site density in all brain regions examined (35-65% of 5-HTT⁺/⁺). In contrast, the density of 5-HT₄ receptor binding sites was not significantly different between heterozygous 5-HTT KO mice (5-HTT⁻/⁺) and 5-HTT⁺/⁺ mice. The 5-HT synthesis inhibitor p-chlorophenylalanine (250 mg/kg twice daily for 3 d) abolished the difference in 5-HT₄ binding between 5-HTT⁻/⁻ and 5-HTT⁺/⁺ mice in all brain regions. Compared to wild-type (WT) littermate controls, 5-HTT OE mice had increased 5-HT₄ binding density across all brain regions, except amygdala (118-164% of WT) and this difference between genotypes was reduced by the 5-HTT inhibitor, fluoxetine (20 mg/kg twice daily, 3 d). Together, these findings suggest that variation in 5-HTT expression causes adaptive changes in 5-HT₄ receptor levels which are directly linked to alterations in 5-HT availability.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21846421     DOI: 10.1017/S1461145711001258

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  7 in total

Review 1.  The SLC6 transporters: perspectives on structure, functions, regulation, and models for transporter dysfunction.

Authors:  Gary Rudnick; Reinhard Krämer; Randy D Blakely; Dennis L Murphy; Francois Verrey
Journal:  Pflugers Arch       Date:  2013-12-13       Impact factor: 3.657

2.  Rapid anxiolytic effects of a 5-HT₄ receptor agonist are mediated by a neurogenesis-independent mechanism.

Authors:  Indira Mendez-David; Denis J David; Flavie Darcet; Melody V Wu; Saadia Kerdine-Römer; Alain M Gardier; René Hen
Journal:  Neuropsychopharmacology       Date:  2013-11-28       Impact factor: 7.853

Review 3.  The Prostaglandin Transporter: Eicosanoid Reuptake, Control of Signaling, and Development of High-Affinity Inhibitors as Drug Candidates.

Authors:  Victor L Schuster; Yuling Chi; Run Lu
Journal:  Trans Am Clin Climatol Assoc       Date:  2015

4.  BDNF Val66met and 5-HTTLPR polymorphisms predict a human in vivo marker for brain serotonin levels.

Authors:  Patrick M Fisher; Klaus K Holst; Dea Adamsen; Anders Bue Klein; Vibe G Frokjaer; Peter S Jensen; Claus Svarer; Nic Gillings; William F C Baare; Jens D Mikkelsen; Gitte M Knudsen
Journal:  Hum Brain Mapp       Date:  2014-09-13       Impact factor: 5.038

5.  Central 5-HT4 receptor binding as biomarker of serotonergic tonus in humans: a [11C]SB207145 PET study.

Authors:  M E Haahr; P M Fisher; C G Jensen; V G Frokjaer; B Mc Mahon; K Madsen; W F C Baaré; S Lehel; A Norremolle; E A Rabiner; G M Knudsen
Journal:  Mol Psychiatry       Date:  2013-11-05       Impact factor: 15.992

6.  Perturbed Developmental Serotonin Signaling Affects Prefrontal Catecholaminergic Innervation and Cortical Integrity.

Authors:  Lidiane P Garcia; Josefine S Witteveen; Anthonieke Middelman; Josephus A van Hulten; Gerard J M Martens; Judith R Homberg; Sharon M Kolk
Journal:  Mol Neurobiol       Date:  2018-06-09       Impact factor: 5.590

7.  Effect of selective serotonin reuptake inhibitor discontinuation on anxiety-like behaviours in mice.

Authors:  Helen M Collins; Raquel Pinacho; Dersu Ozdemir; David M Bannerman; Trevor Sharp
Journal:  J Psychopharmacol       Date:  2022-05-23       Impact factor: 4.562

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.